Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 4Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 7NIH 5NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1Immunoglobulin Light-chain Amyloidosis 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Cisplatin 24Radiotherapy 18Carboplatin 18Paclitaxel 17Vincristine 15Cyclophosphamide 14Etoposide 13Filgrastim 12Doxorubicin 12Gemcitabine 11Temozolomide 10Cytarabine 9Topotecan 8Docetaxel 8Methotrexate 7Irinotecan 7Granulocyte Colony-Stimulating Factor 7Dexamethasone 7Taxes 6Radiation 6Peripheral Blood Stem Cell Transplantation 6Radiotherapy, Conformal 5Oxaliplatin 5Melphalan 5Fenretinide 5Chemotherapy, Adjuvant 5Capecitabine 5etoposide phosphate 4Trastuzumab 4Platinum 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × NETWORK × Amifostine × Clear all
NCT00052884 2023-06-18

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Eastern Cooperative Oncology Group

Phase 1 Terminated
8 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡